Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Dapiglutide

Investigational

Dual GLP-1/GLP-2 receptor agonist

Also known as: Dapiglutide (sodium salt), ZP7570, ZFSPELIJRGIIEX-HLQWLALHSA-N, AT42617, ZP-7570

Evidence score

52/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 2 registered studies on ClinicalTrials.gov, most advanced Phase 2
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Dapiglutide is an investigational, long-acting synthetic peptide developed by Zealand Pharma. It is designed to activate both the GLP-1 and GLP-2 receptors, which are involved in appetite, blood sugar regulation, and the growth and function of the gut lining. It has been studied mainly for short bowel syndrome and has also been explored for obesity.

What the evidence shows

Automatic summaryLimited human data

Dapiglutide is not FDA-approved, and human evidence is limited to a small number of early-stage trials (2 registered, up to Phase 2) with only a few published papers. Its effectiveness and long-term safety in humans have not been established.

Key facts

Molecular formula

C192H302N46O57

Molecular weight

4167 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

2registered studies

Phase 2most advanced phase

1completed (sample)

0recruiting (sample)

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Phase 1CompletedNCT06758583

Dapiglutide for the Treatment of Obesity

Phase 2Active Not RecruitingNCT05788601

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

3papers referencing Dapiglutide

Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel.

JPEN J Parenter Enteral Nutr2022

The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel.

Ann N Y Acad Sci2022

Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.

EClinicalMedicine2026

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.